Scientific article
English

Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists

Published in

Canadian Journal of Cardiology, vol. 34, no. 1, p. 92.e1-92.e3

Publication date

2018

Abstract

The ever-increasing use of immune checkpoint inhibitors in cancer is leading to a high incidence of autoimmune side effects. This report discusses an autoimmune fulminant myocarditis in an elderly patient with metastatic pulmonary adenocarcinoma in whom the most advanced invasive heart failure therapies were used successfully. She was treated with nivolumab. This case illustrates a severe cardiovascular complication of immunotherapy and highlights to cardiologists the importance of aggressive treatments in patients with metastatic cancers whose prognosis has improved dramatically.

Citation (ISO format)

FRIGERI, Mauro et al. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. In: Canadian Journal of Cardiology, 2018, vol. 34, n° 1, p. 92.e1–92.e3. doi: 10.1016/j.cjca.2017.09.025

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0828-282X
545views
2downloads

Technical informations

Creation

03/01/2018 10:06:00

First validation

03/01/2018 10:06:00

Update

15/03/2023 07:45:15

Status update

15/03/2023 07:45:14

Last indexation

31/10/2024 09:21:11
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated